Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents

This study has been withdrawn prior to enrollment.
(Failure to secure adequate funding)
Information provided by:
Creighton University Identifier:
First received: December 28, 2007
Last updated: July 29, 2011
Last verified: July 2011

It is recommended that patients who have drug-eluting stents placed in their coronary arteries take aspirin and Plavix (Clopidogrel) for at least a year. Patients who stop taking these antiplatelet drugs or who have resistance to the antiplatelet effects of these drugs are at a higher risk of clots occurring inside the stents which may result in a heart attack. At the present time, it is unknown if increasing the doses of the antiplatelet agents is effective in overcoming this resistance. The purpose of this project is to identify patients with antiplatelet drug resistance and to test whether an increase in the Plavix (Clopidogrel) dose overcomes antiplatelet drug resistance.

Condition Intervention Phase
Coronary Artery Disease
Drug: Plavix (Clopidogrel)
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Creighton University:

Primary Outcome Measures:
  • to evaluate the frequency of aspirin and Plavix (Clopidogrel) resistance (as measured by a percent inhibition of platelet aggregation) in patients undergoing coronary drug-eluting stent deployment [ Time Frame: 3 month intervals up to 12 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • to assess if a Plavix (Clopidogrel) dose increase in patients with resistance to both aspirin and Plavix (Clopidogrel) is effective in overcoming antiplatelet drug resistance [ Time Frame: 3 month intervals up to 12 months ] [ Designated as safety issue: Yes ]
  • to evaluate the frequency of major adverse cardiovascular events in patients with and without antiplatelet resistance and following a dose increase in Plavix (Clopidogrel). [ Time Frame: 3 month intervals up to 12 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 200
Study Start Date: October 2007
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Plavix (Clopidogrel)
150 mg tablet of Plavix (Clopidogrel) per day for 12 months if resistance is identified


Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Required Coronary Artery Angioplasty with a drug-eluting stent deployment

Exclusion Criteria:

  • The last drug-eluting stent placed greater than 2 weeks prior
  • Aspirin or Plavix (Clopidogrel) allergy or contraindication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00589862

United States, Nebraska
Creighton University Medical Center
Omaha, Nebraska, United States, 68131
Sponsors and Collaborators
Creighton University
Principal Investigator: Daniel Hilleman, PharmD Creighton University
  More Information

No publications provided

Responsible Party: Daniel Hilleman, PharmD, Creighton University Identifier: NCT00589862     History of Changes
Other Study ID Numbers: 07-14622, 07-14622
Study First Received: December 28, 2007
Last Updated: July 29, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Creighton University:
Drug Eluting Stents
Clopidogrel Resistance
Aspirin Resistance

Additional relevant MeSH terms:
Coronary Artery Disease
Arterial Occlusive Diseases
Cardiovascular Diseases
Coronary Disease
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Purinergic Agents
Purinergic Antagonists
Purinergic P2 Receptor Antagonists
Purinergic P2Y Receptor Antagonists
Therapeutic Uses processed this record on March 26, 2015